Mammalian models of aspergillosis

The Aspergilli: Genomics, Medical Aspects, Biotechnology, and Research Methods

Volumn , Issue , 2007, Pages 401-412

  Zaas, Aimee K ^a,b   Steinbach, William J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907821227     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420008517     Document Type: Chapter

References (55)

1. Wiley, J.C., Prattipati, M., Lin, C.P., Ladiges, W., Comparative mouse genomics centers consortium:The mouse genotype database. Mutat Res, 2006. 595(1-2): p. 137-144.
2. Hall, J.E., White, W.J., and Lang, C.M., Acidification of drinking water: Its effects on selected biologic phenomena in male mice. Lab Anim Sci, 1980. 30(4 Pt 1): p. 643-651.
3. Steinbach, W.J., et al., Value of an inhalational model of invasive aspergillosis. Med Mycol, 2004. 42(5):p. 417-425.
4. Steinbach, W.J., et al., Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell, 2006. 5(7): p. 1091-1103.
5. Patterson, T., Invasive aspergillosis animal models: Sop for murine inhalational aspergillosis. 2006.
6. Petraitis, V., et al., Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 2006. 50(4): p. 1510-1507.
7. Balloy, V., et al., Involvement of toll-like receptor 2 in experimental invasive pulmonary aspergillosis. Infect Immun, 2005. 73(9): p. 5420-5425.
8. Bellocchio, S., et al., The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol, 2004. 172(5): p. 3059-3069.
9. Bellocchio, S., et al., TLRs govern neutrophil activity in aspergillosis. J Immunol, 2004. 173(12):p. 7406-7415.
10. Mambula, S.S., et al., Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem, 2002. 277(42): p. 39320-39326.
11. Meier, A., et al., Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol, 2003. 5(8): p. 561-570.
12. Marr, K.A., et al., Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun, 2003. 71(9): p. 5280-5286.
13. Morrison, B.E., et al., Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest, 2003. 112(12): p. 1862-1870.
14. Mehrad, B., Moore, T.A., and Standiford, T.J., Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. J Immunol, 2000. 165(2): p. 962-968.
15. Dennis, C.G., et al., Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother, 2006. 50(2): p. 422-427.
16. Pollock, J.D., et al., Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet, 1995. 9(2): p. 202-209.
17. Chia, R., et al., The origins and uses of mouse outbred stocks. Nat Genet, 2005. 37(11): p. 1181-1186.
18. Maltais, L.J., et al., Rules and guidelines for mouse gene nomenclature: A condensed version. International Committee on Standardized Genetic Nomenclature for Mice. Genomics, 1997. 45(2): p. 471-476.
19. Festing, M.F.W., International Index of Laboratory Animals 6ed. 1993, Newbury, England.
20. Festing, M.F., Warning: The use of heterogeneous mice may seriously damage your research. Neurobiol Aging, 1999. 20(2): p. 237-244; discussion 245-246.
21. Mural, R.J., et al., A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science, 2002. 296(5573): p. 1661-1671.
22. Wade, C.M. and Daly M.J., Genetic variation in laboratory mice. Nat Genet, 2005. 37(11): p. 1175-80.
23. Waterston, R.H., et al., Initial sequencing and comparative analysis of the mouse genome. Nature, 2002. 420(6915): p. 520-562.
24. Francesconi, A., et al., Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol, 2006. 44(7): p. 2475-2480.
25. Walsh, T.J., et al., Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother, 1995. 39(5): p. 1065-1069.
26. Kirkpatrick, W.R., Coco, B.J., and Patterson, T.F., Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother, 2006. 50(4): p. 1567-1569.
27. Bellocchio, S., et al., Immunity to Aspergillus fumigatus: The basis for immunotherapy and vaccination. Med Mycol, 2005. 43 Suppl 1: p. S181-S188.
28. Montagnoli, C., et al., Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol, 2006. 176(3): p. 1712-1723.
29. Stephens-Romero, S.D., Mednick, A.J., and Feldmesser, M., The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect Immun, 2005. 73(1):p. 114-125.
30. Steinbach WJ, Z.A., New animal models of Aspergillus and Candida infections. Discovery Today:Disease Models 2004. doi:10.1016/j.ddmod.2004.03.001.
31. Balloy, V., et al., Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun, 2005. 73(1):p. 494-503.
32. Berenguer, J., et al., Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med, 1995. 152(3):p. 1079-1086.
33. Brummer, E., Choi, J.H., and Stevens, D.A., Interaction between conidia, lung macrophages, immunosuppressants, proinflammatory cytokines and transcriptional regulation. Med Mycol, 2005. 43 Suppl 1:p. S177-S179.
34. Brummer, E., Maqbool, A., and Stevens, D.A., Protection of bronchoalveolar macrophages by granulocyte- macrophage colony-stimulating factor against dexamethasone suppression of fungicidal activity for Aspergillus fumigatus conidia. Med Mycol, 2001. 39(6): p. 509-515.
35. Kamberi, M., Brummer, E., and Stevens, D.A., Regulation of bronchoalveolar macrophage proinflammatory cytokine production by dexamethasone and granulocyte-macrophage colony-stimulating factor after stimulation by Aspergillus conidia or lipopolysaccharide. Cytokine, 2002. 19(1): p. 14-20.
36. Duong, M., et al., Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis, 1998. 178(5): p. 1472-1482.
37. Tang, C.M., et al., The alkaline protease of Aspergillus fumigatus is not a virulence determinant in two murine models of invasive pulmonary aspergillosis. Infect Immun, 1993. 61(5): p. 1650-1656.
38. Dixon, D.M., Polak, A., and Walsh, T.J., Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun, 1989. 57(5): p. 1452-1456.
39. Piggott, W.R.a.E., C.W, Device for inhalation exposure of animals to spores. Proc Soc Exp Biol Med, 1960. 103: p. 805-806.
40. Sheppard, D.C., et al., Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 2004. 48(5): p. 1908-1911.
41. Patterson, T.F., The future of animal models of invasive aspergillosis. Med Mycol, 2005. 43 Suppl 1:p. S115-119.
42. Clemons, K.V. and Stevens, D.A., Comparative efficacies of four amphotericin B formulations-Fungizone, amphotec (Amphocil), AmBisome, and Abelcet-against systemic murine aspergillosis. Antimicrob Agents Chemother, 2004. 48(3): p. 1047-1050.
43. Takemoto, K., et al., Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother, 2004. 53(2): p. 311-317.
44. Takemoto, K., et al., Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother, 2006. 57(4): p. 724-731.
45. Denning, D.W. and Stevens, D.A., Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother, 1991. 35(7): p. 1329-1333.
46. Chiller, T.M., et al., Development of a murine model of cerebral aspergillosis. J Infect Dis, 2002. 186(4):p. 574-577.
47. Nawada, R., et al., Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection. J Clin Microbiol, 1996. 34(6): p. 1433-1439.
48. Adler-Moore, J.P., Olson, J.A., and Proffitt, R.T., Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother, 2004. 54(6): p. 1096-1102.
49. Sasaki, S., et al., The role of gamma interferon in acquired host resistance against Staphylococcus aureus infection in mice. FEMS Immunol Med Microbiol, 2006. 46(3): p. 367-374.
50. Bowman, J.C., et al., Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother, 2001. 45(12): p. 3474-3481.
51. Sheppard, D.C., et al., Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clin Microbiol Infect, 2006. 12(4): p. 376-380.
52. Petraitiene, R., et al., Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother, 2002. 46(1): p. 12-23.
53. Petraitis, V., et al., Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother, 2002. 46(6): p. 1857-1869.
54. Lehmann, P.F. and White, L.O. Chitin assay used to demonstrate renal localization and cortisone-enhanced growth of Aspergillus fumigatus mycelium in mice. Infect Immun, 1975. 12(5): p. 987-992.
55. Mehrad, B., Strieter, R.M., and Standiford, T.J., Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol, 1999. 162(3): p. 1633-1640.